A first in India: Zydus brings a new drug for uncontrolled ‘bad’ cholesterol

0
5

For the first time in India, Limited (formerly Cadila Healthcare Ltd) has launched a new class of drug ‘Bemdac’ to treat uncontrolled low-density lipoprotein (LDL-c).

Since uncontrolled LDL-c presented a significant risk of developing cardiovascular diseases, it lacked adequate treatment despite changes in the patients’ lifestyle and the use of the maximum tolerated dose of statins. However, now that it addresses the pressing need for medical attention, the oral drug Bemdac will offer a new line of treatment for patients with uncontrolled levels of LDL-c.

Often referred to as bad Since it is deposited on the walls of blood vessels, LDL-C increases the chances of health problems such as heart attack or stroke.

Currently uncontrolled LDL-c leads to an imbalance of lipids, including cholesterol, LDL-c, triglycerides, and high-density lipoproteins (HDL), commonly known as dyslipidemia. Citing various studies, on Friday stated that eight out of 10 Indians are dyslipidemic and 112 million adults suffer from high levels of LDL-c.

In addition, seven out of 10 patients with dyslipidemia who are taking statins continue to suffer from uncontrolled LDL-c. Additionally, 5.4 million Indians are intolerant to statin therapy. However, Bemdac’s bempedoic acid has also shown good results in patients who cannot tolerate statins and those who do not respond to statins.

As Zydus already has several leading brands to address cardiac care and dyslipidemia, including Atorva, Clopitorva, Zyrova and Pivasta, Bemdac is now an important addition to the company’s portfolio of medicines to manage dyslipidemia and cholesterol, said the managing director of Zydus Lifesciences, Dr. Sharvil Patel.

For example, the company’s brand, Atorva, is the market leader for atorvastatin with a market share of 18.4%, ranking second in terms of market share in the statin segment at Rs 2,162 crore , according to the AWACS Report of February 2022.

Dear reader,

Business Standard has always strived to provide up-to-date information and commentary on developments that are of interest to you and have broader political and economic implications for the country and the world. Your constant encouragement and feedback on how to improve our offering has only strengthened our resolve and commitment to these ideals. Even during these challenging times stemming from Covid-19, we remain committed to keeping you informed and up-to-date with credible news, authoritative viewpoints, and incisive commentary on relevant current issues.
We, however, have a request.

As we grapple with the economic impact of the pandemic, we need your support even more so that we can continue to bring you more quality content. Our subscription model has seen an encouraging response from many of you who have subscribed to our online content. More subscriptions to our online content can only help us achieve our goals of bringing you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practice the journalism we are committed to.

Support quality journalism and subscribe to Business Standard.

digital copywriter

LEAVE A REPLY

Please enter your comment!
Please enter your name here